Arcellx, Inc.
ACLX
Rank in Stocks
#2788
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Share Price
$115.07
Last synced: 2026-05-15
Market Cap
$6.73B
Change (1 day)
0.00%
Change (1 year)
32.61%
Country
US
Trade Arcellx, Inc. (ACLX)
Category
Healthcare
P/E ratio for Arcellx, Inc. (ACLX)
P/E ratio as of October 2026 TTM: -39.14
According to Arcellx, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -39.14. At the end of 2023 the company had a P/E ratio of -37.73.
P/E ratio history for Arcellx, Inc. from 2018 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -39.14 | 2.27% |
| 2024 | -38.27 | 1.42% |
| 2023 | -37.73 | 421.05% |
| 2022 | -7.24 | -17.85% |
| 2021 | -8.82 | -22.67% |
| 2020 | -11.40 | -64.94% |
| 2019 | -32.51 | 9,611.14% |
| 2018 | -0.33 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -173.54% |
US
|
|
| -28.36 | -27.55% |
US
|
|
| -24.57 | -37.23% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -177.49% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.